Alternating Regimen of VA and Low-dose CHA in the Treatment of Unfit Newly Diagnosed AML
Status:
RECRUITING
Trial end date:
2029-07-31
Target enrollment:
Participant gender:
Summary
This phase II trial tests how well VA alternating with low-dose CHA works in treating unfit patients with newly diagnosed acute myeloid leukemia (AML). This is a prospective, multi-centers, single arm phase II study aimed to overcome VEN resistance and achieve greater MRD negative rate, providing better control of treatment for unfit AML.